Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective

Moderna is the second company to report preliminary results from a large trial testing a vaccine. But there are still months to go before it will be widely available to the public.

 

By Denise Grady, The New York Times (NYT)

Nov. 16, 2020  

 

The drugmaker Moderna announced on Monday that its coronavirus vaccine was 94.5 percent effective, based on an early look at the results from its large, continuing study.

 

Researchers said the results were better than they had dared to imagine. But the vaccine will not be widely available for months, probably not until spring.

 

Moderna is the second company to report preliminary data on an apparently successful vaccine, offering hope in a surging pandemic that has infected more than 53 million people worldwide and killed more than 1.2 million. Pfizer, in collaboration with BioNTech, was the first, reporting one week ago that its vaccine was more than 90 percent effective.

 

Pfizer and Moderna were the first to announce early data on large studies, but 10 other companies are also conducting big Phase 3 trials in a global race to produce a vaccine, including efforts in Australia, Britain, China, India and Russia. More than 50 other candidates are in earlier stages of testing.

 

The Food and Drug Administration has said that coronavirus vaccines should be at least 50 percent effective to be approved.

 

Researchers test vaccines by inoculating some study participants and giving others placebos, and then watching the two groups to see how many people get sick. In Moderna’s study, 95 people contracted the coronavirus: five who were vaccinated, and 90 who received placebo shots of saltwater. Statistically, the difference between the two groups was highly significant. And of the 95 cases, 11 were severe — all in the placebo group.

 

The results were analyzed by an independent data safety monitoring board, appointed by the National Institutes of Health.

 

Moderna, based in Cambridge, Mass., developed its vaccine in collaboration with researchers from the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases.

 

Dr. Anthony S. Fauci, director of the institute, said in an interview:

 

more

https://www.nytimes.com/2020/11/16/health/Covid-moderna-vaccine.html